Hypoxic Conditioned Medium Secretome from Mesenchymal Stem Cell Alleviates Sepsis by Targeting IL-6 and IL-4

Area of Science:

• Immunology
• Regenerative Medicine
• Sepsis Research

Background:

• Sepsis involves immune system imbalance during infection.
• Mesenchymal stem cell (MSC) secretomes, particularly hypoxic conditioned medium (HPO-CM) secretome, show potential for immunomodulatory therapy.

Purpose of the Study:

• To investigate the therapeutic effects of HPO-CM secretome on immune markers in a rat model of sepsis.
• To analyze the impact of HPO-CM secretome on Interleukin-6 (IL-6) and Interleukin-4 (IL-4) levels.

Main Methods:

• A rat model of sepsis was established.
• Rats were divided into sham, control, and two treatment groups receiving different doses of HPO-CM secretome (150 µL and 300 µL).
• Serum levels of IL-6 and IL-4 were measured 48 hours post-sepsis induction.

Main Results:

• Treatment with HPO-CM secretome significantly decreased IL-6 levels in both the 150 µL and 300 µL groups.
• A significant increase in IL-4 levels was observed in rats treated with 300 µL of HPO-CM secretome.

Conclusions:

• HPO-CM secretome demonstrates efficacy in mitigating immune dysregulation associated with sepsis.
• The findings suggest HPO-CM secretome can modulate sepsis-induced inflammation by reducing pro-inflammatory IL-6 and enhancing anti-inflammatory IL-4.